405 institutions hold shares in CRISPR Therapeutics AG (CRSP), with 10.34M shares held by insiders accounting for 13.71% while institutional investors hold 79.38% of the company’s shares. The shares outstanding are 71.32M, and float is at 64.13M with Short Float at 5.86%. Institutions hold 68.49% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is ARK Investment Management, LLC with over 10.41 million shares valued at $1.59 billion. The investor’s holdings represent 13.81% of the CRSP Shares outstanding. As of Dec 30, 2020, the second largest holder is Capital International Investors with 7.43 million shares valued at $1.14 billion to account for 9.85% of the shares outstanding. The other top investors are Nikko Asset Management Americas, Inc. which holds 3.84 million shares representing 5.09% and valued at over $587.46 million, while Versant Venture Management, LLC holds 4.03% of the shares totaling 3.04 million with a market value of $465.53 million.
CRISPR Therapeutics AG (NASDAQ: CRSP) is -17.39% lower on its value in year-to-date trading and has touched a low of $37.01 and a high of $220.20 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CRSP stock was last observed hovering at around $133.00 in the last trading session, with the day’s loss setting it -6.51% off its average median price target of $165.00 for the next 12 months. It is also 39.77% off the consensus price target high of $210.00 offered by 20 analysts, but current levels are -181.09% lower than the price target low of $45.00 for the same period.
Currently trading at $126.49, the stock is -0.42% and -18.06% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.79 million and changing -4.89% at the moment leaves the stock 10.68% off its SMA200. CRSP registered 219.90% gain for a year compared to 6-month gain of 48.58%. The firm has a 50-day simple moving average (SMA 50) of $140.18 and a 200-day simple moving average (SMA200) of $128.84.
The stock witnessed a -8.71% loss in the last 1 month and extending the period to 3 months gives it a -14.88%, and is -3.12% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.25% over the week and 7.76% over the month.
CRISPR Therapeutics AG (CRSP) has around 410 employees, a market worth around $9.10B and $0.70M in sales. Distance from 52-week low is 241.77% and -42.56% from its 52-week high. The company has generated returns on investments over the last 12 months (-21.30%).
CRISPR Therapeutics AG (CRSP) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for CRISPR Therapeutics AG (CRSP) is a “Overweight”. 20 analysts offering their recommendations for the stock have an average rating of 2.40, where 7 rate it as a Hold and 0 think it is a “Overweight”. 11 of the analysts rate the stock as a “Buy”. 2 analysts have rated the stock as a Sell or Underperform.
CRISPR Therapeutics AG is expected to release its quarterly report on 05/12/2021 and quarterly earnings per share for the current quarter are estimated at -$1.49 with sales reaching $1.21M over the same period.The EPS is expected to shrink by -550.50% this year, but quarterly earnings will post 1,299.20% year-over-year. Quarterly sales are estimated to shrink -60.20% in year-over-year returns.
CRISPR Therapeutics AG (CRSP) Insider Activity
A total of 141 insider transactions have happened at CRISPR Therapeutics AG (CRSP) in the last six months, with sales accounting for 108 and purchases happening 33 times. The most recent transaction is an insider sale by Bolzon Bradley J PhD, the company’s Director. SEC filings show that Bolzon Bradley J PhD sold 171,003 shares of the company’s common stock on Feb 19 at a price of $149.11 per share for a total of $25.5 million. Following the sale, the insider now owns 0.17 million shares.
CRISPR Therapeutics AG disclosed in a document filed with the SEC on Jan 19 that KASINGER JAMES R. (General Counsel and Secretary) sold a total of 27,500 shares of the company’s common stock. The trade occurred on Jan 19 and was made at $204.94 per share for $5.64 million. Following the transaction, the insider now directly holds 22431.0 shares of the CRSP stock.
Still, SEC filings show that on Jan 15, Klein Lawrence Otto (CBO & COO) disposed off 25,000 shares at an average price of $215.20 for $5.38 million. The insider now directly holds 20,000 shares of CRISPR Therapeutics AG (CRSP).
CRISPR Therapeutics AG (CRSP): Who are the competitors?
The company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading 24.88% up over the past 12 months. Short interest in the company’s stock has risen 21.33% from the last report on Jan 28, 2021 to stand at a total of 2.95 million short shares sold with a short interest ratio of 1.57.